Evidence supporting the use of: Resveratrol
For the health condition: Fibrosis

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Resveratrol, a naturally occurring polyphenol found in grapes, berries, and peanuts, has been investigated in recent years for its potential anti-fibrotic properties. While there is no robust clinical evidence for its use in treating fibrosis in humans, a growing body of preclinical studies suggests that resveratrol may help modulate fibrosis-related pathways. In animal models and cell culture studies, resveratrol has demonstrated the ability to attenuate fibrosis in various organs, including the liver, lungs, heart, and kidneys. Proposed mechanisms include inhibition of TGF-β signaling, reduction of oxidative stress, suppression of inflammatory cytokines, and prevention of myofibroblast activation and extracellular matrix deposition. Despite encouraging preclinical data, human studies are lacking. There have been no large randomized controlled trials directly evaluating resveratrol as a treatment for fibrotic disorders. Most of the available literature consists of cell-based or animal experiments. Potential limitations include poor bioavailability of resveratrol in humans and uncertainty regarding effective dosing. Thus, while the scientific rationale for resveratrol’s anti-fibrotic effects is supported by experimental data, clinical validation is currently insufficient. In summary, resveratrol’s use for fibrosis is justified by scientific investigation at the preclinical level, but its efficacy and safety in humans remain unproven. More clinical research is needed before resveratrol can be recommended as a therapy for fibrosis.

More about resveratrol
More about Fibrosis